Two biotechs—Seaport Therapeutics and Hemab Therapeutics—priced IPOs in the latest wave of enlarged debuts, adding to a 2026 IPO resurgence. Seaport’s offering raised $254.9 million gross proceeds by listing on Nasdaq, while Hemab priced an upsized $301.5 million gross offering with an additional potential overallotment. The IPO momentum reflects investor appetite for development-stage platforms in CNS and coagulation disorders, with both companies positioned to fund clinical progress as public-market access remains a priority for late preclinical and early clinical biotechs. Together with other recent deals mentioned in related coverage, the filings point to continued underwriting support for biotech flotations after a brief slowdown in earlier months.